{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:27:49Z","timestamp":1769005669111,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Comorbidities impair the prognosis of diffuse large B-cell lymphoma (DLBCL). Type 2 diabetes mellitus (DMT2) increases the risk of other comorbidities, e.g., heart failure (HF). Thus, we hypothesized that pre-existing DMT2 may negatively affect the outcome of DLBCL. To verify this, DLBCL patients treated with (R)-CHOP were enrolled. 469 patients were eligible, with a median age of 57 years; 356 patients had advanced-stage DLBCL. 126 patients had high-intermediate and 83 high-risk international prognostic index (IPI). Seventy-six patients had DMT2, 46 HF; 26 patients suffered from both DMT2 and HF. In the analyzed group DMT2 or HF significantly shortened overall survival (OS) and progression free survival (PFS): the 5-year OS for patients with DMT2 was 64% vs 79% and for those with HF: 49% vs 79%. The 5-year PFS for DMT2 was 50.6% vs 62.5% and for HF 39.4% vs 63.2%. The relapse\/progression incidence was comparable between groups; the non-relapse\/progression mortality (NRPM) was significantly higher solely in DMT2 patients (5-year NRPM 22.5% vs 8.4%). The risk of death was higher in patients with higher IPI (HR\u2009=\u20091.85) and with DMT2 (HR\u2009=\u20091.87). To conclude, pre-existing DMT2, in addition to a higher IPI and HF, was a negative predictor for OS and PFS.<\/jats:p>","DOI":"10.1038\/s41598-020-60565-7","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:03:19Z","timestamp":1582714999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP \u2013 the PLRG report"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6264","authenticated-orcid":false,"given":"Joanna","family":"Drozd-Sokolowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-8936","authenticated-orcid":false,"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemyslaw","family":"Biecek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Giza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kobylinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Joks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Wrobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Kumiega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanda","family":"Knopinska-Posluszny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Spychalowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Romejko-Jarosinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wieslaw","family":"Wiktor-Jedrzejczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Dlugosz-Danecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"60565_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/17474086.2015.1024650","volume":"8","author":"C Terret","year":"2015","unstructured":"Terret, C., Albrand, G., Rainfray, M. & Soubeyran, P. Impact of comorbidities on the treatment of non-Hodgkin\u2019s lymphoma: a systematic review. Expert. Rev. Hematol. 8, 329\u2013341, https:\/\/doi.org\/10.1586\/17474086.2015.1024650 (2015).","journal-title":"Expert. Rev. Hematol."},{"key":"60565_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00277-015-2358-3","volume":"94","author":"MW van der Poel","year":"2015","unstructured":"van der Poel, M. W. et al. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study. Ann. Hematol. 94, 1373\u20131379, https:\/\/doi.org\/10.1007\/s00277-015-2358-3 (2015).","journal-title":"Ann. Hematol."},{"key":"60565_CR3","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-08-3392","volume":"107","author":"EC Moser","year":"2006","unstructured":"Moser, E. C. et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107, 2912\u20132919, https:\/\/doi.org\/10.1182\/blood-2005-08-3392 (2006).","journal-title":"Blood"},{"key":"60565_CR4","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1200\/JCO.1998.16.6.2070","volume":"16","author":"TB Haddy","year":"1998","unstructured":"Haddy, T. B. et al. Late effects in long-term survivors of high-grade non-Hodgkin\u2019s lymphomas. J. Clin. oncology: Off. J. Am. Soc. Clin. Oncol. 16, 2070\u20132079, https:\/\/doi.org\/10.1200\/JCO.1998.16.6.2070 (1998).","journal-title":"J. Clin. oncology: Off. J. Am. Soc. Clin. Oncol."},{"key":"60565_CR5","unstructured":"Jurczak, W. et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - A national multicenter study. Int J Cardiol, doi:S0167-5273(13)01558-1 (2013)."},{"key":"60565_CR6","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/cncr.22188","volume":"107","author":"VR Grann","year":"2006","unstructured":"Grann, V. R. et al. Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 107, 1530\u20131541, https:\/\/doi.org\/10.1002\/cncr.22188 (2006).","journal-title":"Cancer"},{"key":"60565_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijcard.2017.02.073","volume":"235","author":"S Szmit","year":"2017","unstructured":"Szmit, S. et al. Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders. Int. J. Cardiol. 235, 147\u2013153, https:\/\/doi.org\/10.1016\/j.ijcard.2017.02.073 (2017).","journal-title":"Int. J. Cardiol."},{"key":"60565_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3892\/mmr.2014.2341","volume":"10","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Diabetes mellitus potentiates diffuse large Bcell lymphoma via high levels of CCL5. Mol. Med. Rep. 10, 1231\u20131236, https:\/\/doi.org\/10.3892\/mmr.2014.2341 (2014).","journal-title":"Mol. Med. Rep."},{"key":"60565_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0165-2478(01)00178-X","volume":"76","author":"MH Lehmann","year":"2001","unstructured":"Lehmann, M. H., Schreiber, S., Vogelsang, H. & Sigusch, H. H. Constitutive expression of MCP-1 and RANTES in the human histiocytic lymphoma cell line U-937. Immunology Lett. 76, 111\u2013113 (2001).","journal-title":"Immunology Lett."},{"key":"60565_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. oncology: Off. J. Am. Soc. Clin. Oncol. 25, 579\u2013586, https:\/\/doi.org\/10.1200\/JCO.2006.09.2403 (2007).","journal-title":"J. Clin. oncology: Off. J. Am. Soc. Clin. Oncol."},{"key":"60565_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","year":"1993","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N. Engl. J. Med. 329, 987\u2013994, https:\/\/doi.org\/10.1056\/NEJM199309303291402 (1993).","journal-title":"N. Engl. J. Med."},{"key":"60565_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/eurheartj\/ehw128","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. J. Heart Fail. 18, 891\u2013975, https:\/\/doi.org\/10.1093\/eurheartj\/ehw128 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"60565_CR13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/biomet\/87.3.706","volume":"87","author":"G Imbens","year":"2000","unstructured":"Imbens, G. The role of the propensity score in estimating dose-response functions. Biometrika 87, 706\u2013710, https:\/\/doi.org\/10.1093\/biomet\/87.3.706 (2000).","journal-title":"Biometrika"},{"key":"60565_CR14","unstructured":"Exploring propensity score matching and weighting, http:\/\/freerangestats.info\/blog\/2017\/04\/09\/propensity-v-regression (2017)."},{"key":"60565_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/01.cej.0000236253.93984.8f","volume":"16","author":"SY Lin","year":"2007","unstructured":"Lin, S. Y. et al. Diabetes mellitus associated with the occurrence and prognosis of non-Hodgkin\u2019s lymphoma. Eur. J. Cancer Prev. 16, 471\u2013478, https:\/\/doi.org\/10.1097\/01.cej.0000236253.93984.8f (2007).","journal-title":"Eur. J. Cancer Prev."},{"key":"60565_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.metabol.2011.11.015","volume":"61","author":"CH Tseng","year":"2012","unstructured":"Tseng, C. H. Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan. Metab. 61, 1003\u20131009, https:\/\/doi.org\/10.1016\/j.metabol.2011.11.015 (2012).","journal-title":"Metab."},{"key":"60565_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00277-013-1789-y","volume":"92","author":"HJ Lu","year":"2013","unstructured":"Lu, H. J. et al. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era. Ann. Hematol. 92, 1495\u20131501, https:\/\/doi.org\/10.1007\/s00277-013-1789-y (2013).","journal-title":"Ann. Hematol."},{"key":"60565_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00432-010-0973-x","volume":"137","author":"Y Kobayashi","year":"2011","unstructured":"Kobayashi, Y. et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J. Cancer Res. Clin. Oncol. 137, 1079\u20131084, https:\/\/doi.org\/10.1007\/s00432-010-0973-x (2011).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"60565_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00277-017-3170-z","volume":"97","author":"D Antic","year":"2018","unstructured":"Antic, D. et al. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities. Ann. Hematol. 97, 267\u2013276, https:\/\/doi.org\/10.1007\/s00277-017-3170-z (2018).","journal-title":"Ann. Hematol."},{"key":"60565_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ajh.25107","volume":"93","author":"E Pardal","year":"2018","unstructured":"Pardal, E. et al. A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group. Am. J. Hematol. 93, 867\u2013873, https:\/\/doi.org\/10.1002\/ajh.25107 (2018).","journal-title":"Am. J. Hematol."},{"key":"60565_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ajh.24819","volume":"92","author":"C Saygin","year":"2017","unstructured":"Saygin, C. et al. Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. Am. J. Hematol. 92, 989\u2013996, https:\/\/doi.org\/10.1002\/ajh.24819 (2017).","journal-title":"Am. J. Hematol."},{"key":"60565_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/bjh.12765","volume":"165","author":"A Wieringa","year":"2014","unstructured":"Wieringa, A. et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br. J. Haematol. 165, 489\u2013496, https:\/\/doi.org\/10.1111\/bjh.12765 (2014).","journal-title":"Br. J. Haematol."},{"key":"60565_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2141.2011.08934.x","volume":"156","author":"C Nabhan","year":"2012","unstructured":"Nabhan, C. et al. Analysis of very elderly (>\/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br. J. Haematol. 156, 196\u2013204, https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08934.x (2012).","journal-title":"Br. J. Haematol."},{"key":"60565_CR24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1093\/annonc\/mdt282","volume":"24","author":"A Trebouet","year":"2013","unstructured":"Trebouet, A. et al. Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Ann. Oncol. 24, 2612\u20132618, https:\/\/doi.org\/10.1093\/annonc\/mdt282 (2013).","journal-title":"Ann. Oncol."},{"key":"60565_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/joim.12849","volume":"285","author":"T Wasterlid","year":"2019","unstructured":"Wasterlid, T. et al. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study. J. Intern. Med. 285, 455\u2013468, https:\/\/doi.org\/10.1111\/joim.12849 (2019).","journal-title":"J. Intern. Med."},{"key":"60565_CR26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/annonc\/mdr411","volume":"23","author":"SA van de Schans","year":"2012","unstructured":"van de Schans, S. A. et al. Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann. Oncol. 23, 1280\u20131286, https:\/\/doi.org\/10.1093\/annonc\/mdr411 (2012).","journal-title":"Ann. Oncol."},{"key":"60565_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04495-x","volume":"7","author":"C Dendle","year":"2017","unstructured":"Dendle, C. et al. Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma. Sci. Rep. 7, 4395, https:\/\/doi.org\/10.1038\/s41598-017-04495-x (2017).","journal-title":"Sci. Rep."},{"key":"60565_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli, M. et al. Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 87, 146\u2013171, https:\/\/doi.org\/10.1016\/j.critrevonc.2012.12.009 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"60565_CR29","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/annonc\/mdm563","volume":"19","author":"C Thieblemont","year":"2008","unstructured":"Thieblemont, C. et al. Non-Hodgkin\u2019s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann. Oncol. 19, 774\u2013779, https:\/\/doi.org\/10.1093\/annonc\/mdm563 (2008).","journal-title":"Ann. Oncol."},{"key":"60565_CR30","doi-asserted-by":"publisher","unstructured":"Lin, T. L. et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol, https:\/\/doi.org\/10.1007\/s00277-012-1463-9 (2012).","DOI":"10.1007\/s00277-012-1463-9"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60565-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60565-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60565-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:43:22Z","timestamp":1670312602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60565-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60565"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60565-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3517"}}